	Type	Hits	Search Text	DBs
1	BRS	2	9629079.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB
2	BRS	2	6248732.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB
3	BRS	3	5876709.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB
4	BRS	3	5656200.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB
5	BRS	0	514/167.ccls	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB
6	BRS	601	514/167.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB
7	BRS	2615	langerhans	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB
8	BRS	1	514/167.ccls. and langerhans	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB

	Time Stamp	Comments	Error Definition	Errors
1	2003/04/01 18:28			0
2	2002/07/17 17:41			0
3	2002/07/18 13:45			0
4	2002/07/18 13:46			0
5	2003/04/01 18:28			0
6	2003/04/01 18:28			0
7	2003/04/01 18:28			0
8	2003/04/01 18:29			0

Welcome to STN International! Enter x:x

LOGINID:ssspta1617srh

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4	Apr 09	ZDB will be removed from STN
NEWS 5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 9	Jun 03	New e-mail delivery for search results now available
NEWS 10	Jun 10	MEDLINE Reload
NEWS 11	Jun 10	PCTFULL has been reloaded
NEWS 12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS 13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS 14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS 15	Jul 30	NETFIRST to be removed from STN
NEWS 16	Aug 08	CANCERLIT reload
NEWS 17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18	Aug 08	NTIS has been reloaded and enhanced
NEWS 19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 23	Sep 03	JAPIO has been reloaded and enhanced
NEWS 24	Sep 16	Experimental properties added to the REGISTRY file
NEWS 25	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 26	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27	Oct 21	EVENTLINE has been reloaded
NEWS 28	Oct 24	BEILSTEIN adds new search fields
NEWS 29	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 30	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS 31	Nov 18	DKILIT has been renamed APOLLIT
NEWS 32	Nov 25	More calculated properties added to REGISTRY
NEWS 33	Dec 02	TIBKAT will be removed from STN
NEWS 34	Dec 04	CSA files on STN
NEWS 35	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 36	Dec 17	TOXCENTER enhanced with additional content
NEWS 37	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 38	Dec 30	ISMEC no longer available
NEWS 39	Jan 21	NUTRACEUT offering one free connect hour in February 2003
NEWS 40	Jan 21	PHARMAML offering one free connect hour in February 2003
NEWS 41	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 42	Feb 13	CANCERLIT is no longer being updated
NEWS 43	Feb 24	METADEX enhancements
NEWS 44	Feb 24	PCTGEN now available on STN
NEWS 45	Feb 24	TEMA now available on STN

```
 NEWS 46   Feb 26  NTIS now allows simultaneous left and right truncation
 NEWS 47   Feb 26  PCTFULL now contains images
 NEWS 48   Mar 04  SDI PACKAGE for monthly delivery of multifile SDI results
 NEWS 49   Mar 19  APOLLIT offering free connect time in April 2003
 NEWS 50   Mar 20  EVENTLINE will be removed from STN
 NEWS 51   Mar 24  PATDPAFULL now available on STN
 NEWS 52   Mar 24  Additional information for trade-named substances without
                   structures available in REGISTRY
 NEWS 53   Mar 24  Indexing from 1957 to 1966 added to records in CA/CAPLUS

 NEWS EXPRESS  January 6 CURRENT WINDOWS VERSION IS V6.01a,
               CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *



FILE 'HOME' ENTERED AT 10:53:06 ON 01 APR 2003

=> fil medl hcapl biosis uspatf
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     1.47       1.47

FILE 'MEDLINE' ENTERED AT 10:57:25 ON 01 APR 2003

FILE 'HCAPLUS' ENTERED AT 10:57:25 ON 01 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 10:57:25 ON 01 APR 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'USPATFULL' ENTERED AT 10:57:25 ON 01 APR 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s langerhans
L1         68689 LANGERHANS

=> s migration
L2        350794 MIGRATION

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
```

```
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                      4.74       6.21

FILE 'REGISTRY' ENTERED AT 10:57:58 ON 01 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   31 MAR 2003  HIGHEST RN 501072-24-8
DICTIONARY FILE UPDATES:  31 MAR 2003  HIGHEST RN 501072-24-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> s calcitriol/cn
L3            1 CALCITRIOL/CN

=> d

L3   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2003 ACS
RN   32222-06-3  REGISTRY
CN   9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, (1.alpha.,3.beta.,5Z,7E)-
      (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   1,25-Dihydroxycholecalciferol
CN   1,25-Dihydroxyvitamin D
CN   1,25-Dihydroxyvitamin D3
CN   1.alpha.,25-(OH)2D3
CN   1.alpha.,25-Dihydroxycholecalciferol
CN   1.alpha.,25-Dihydroxyvitamin D3
CN   Calcijex
CN   Calcitriol
CN   Ro 21-5535
CN   Rocaltrol
CN   Silkis
CN   Soltriol
CN   Topitriol
CN   Toptriol
FS   STEREOSEARCH
DR   125338-24-1
MF   C27 H44 O3
CI   COM
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
       BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT,
       CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU,
       DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE,
       MRCK*, NAPRALERT, NIOSHTIC, PHAR, PHARMASEARCH, PROMT, RTECS*,
       TOXCENTER, USAN, USPAT2, USPATFULL, VETU
         (*File contains numerically searchable property data)
```

Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

9248 REFERENCES IN FILE CA (1962 TO DATE)
268 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
9256 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> sel name rn
E1 THROUGH E15 ASSIGNED

=> FIL MEDL HCAPL BIOSIS USPATF

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	6.67	12.88

FILE 'MEDLINE' ENTERED AT 10:58:25 ON 01 APR 2003

FILE 'HCAPLUS' ENTERED AT 10:58:25 ON 01 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 10:58:25 ON 01 APR 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'USPATFULL' ENTERED AT 10:58:25 ON 01 APR 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s e1-15
L4 40698 (CALCIJEX/BI OR CALCITRIOL/BI OR "RO 21-5535"/BI OR ROCALTROL/BI OR SILKIS/BI OR SOLTRIOL/BI OR TOPITRIOL/BI OR TOPTRIOL/BI OR "1.ALPHA.,25-(OH)2D3"/BI OR "1.ALPHA.,25-DIHYDROXYCHOLECALCIFEROL"/BI OR "1.ALPHA.,25-DIHYDROXYVITAMIN D3"/BI OR "1,25-DIHYDROXYCHOLECALCIFEROL"/BI OR "1,25-DIHYDROXYVITAMIN D"/BI OR "1,25-DIHYDROXYVITAMIN D3"/BI OR 32222-06-3/BI)

=> s l4 and l1 and l2
L5 13 L4 AND L1 AND L2

=> dup rem l5
PROCESSING COMPLETED FOR L5
L6 12 DUP REM L5 (1 DUPLICATE REMOVED)

=> d ibib abs tot

L6 ANSWER 1 OF 12 USPATFULL

ACCESSION NUMBER: 2003:86817 USPATFULL
TITLE: Immune modulation method using steroid compounds
INVENTOR(S): Ahlem, Clarence N., San Diego, CA, UNITED STATES
Frincke, James M., San Diego, CA, UNITED STATES
dos Anjos de Carvalho, Luis Daniel, Paio Pires, PORTUGAL
Heggie, William, Palmela, PORTUGAL
Prendergast, Patrick T., County Kildare, IRELAND
Reading, Christopher L., San Diego, CA, UNITED STATES
Thadikonda, Krupakar Paul, Gaithersburg, MD, UNITED STATES
Vernon, Russell N., Oak Hills, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003060425	A1	20030327
APPLICATION INFO.:	US 2001-820483	A1	20010329 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-449184, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-414905, filed on 8 Oct 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449004, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-535675, filed on 23 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1999-449042, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-675470, filed on 28 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-586673, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-586672, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-461026, filed on 15 Dec 1999, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-109924P	19981124 (60)
	US 1999-140028P	19990616 (60)
	US 1998-109923P	19981124 (60)
	US 1999-126056P	19991019 (60)
	US 1999-124087P	19990311 (60)
	US 1998-110127P	19981127 (60)
	US 1999-161453P	19991025 (60)
	US 1999-145823P	19990727 (60)
	US 1999-137745P	19990603 (60)
	US 1998-112206P	19981215 (60)
	US 2000-257071P	20001220 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL, SUITE 400, SAN DIEGO, CA, 92121
NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 14708
AB The invention provides compositions comprising formula 1 steroids, e.g.,

16.alpha.-bromo-3 .beta.-hydroxy-5.alpha.-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v/v water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16.alpha.-bromo-3.beta.-hydroxy-5.alpha.-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using the compounds. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

L6 ANSWER 2 OF 12 USPATFULL
ACCESSION NUMBER: 2002:344627 USPATFULL
TITLE: THERAPEUTIC USE OF THE SMR 1 PROTEIN AND ACTIVE DERIVATIVES THEREOF
INVENTOR(S): ROUGEOT, CATHERINE, CHEVREU, FRANCE
ROUGEON, FRANCOIS, POIGNY LA FORET, FRANCE

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002198361	A1	20021226	
APPLICATION INFO.:	US 1999-367703	A1	19991013	(9)
	WO 1998-EP956		19980219	

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT, 1755 JEFFERSON DAVIS HIGHWAY, FOURTH FLOOR, ARLINGTON, VA, 22202
NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Page(s)
LINE COUNT: 2466
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention pertains to the use of a peptide molecule consisting in a maturation product of SMR (Submandibular rat protein 1) of structural formula QHNPR, as well as the biologically active derivatives of the said peptide, for preventing or treating diseases associated with a mineral ion imbalance in a human or an animal body. More particularly, the present invention relates to the therapeutic use of the above-cited molecules for preventing or treating an hydromineral imbalance in organs and tissues such as kidney, bone, dental enamel, dental ivory, gut matrix, pancreas or glandular gastric mucosa. This invention also deals with therapeutic compositions comprising a pharmaceutically active amount of the above-described therapeutic molecoles as well as with therapeutic methods using the said therapeutic compostions. Finally, the present invention rekates to processes for selecting ligand molecules that posses an agonist or an antagonist biological activity on the target receptor of the QHNPR pentapeptide as well as to be selected ligand molecules themselves.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 3 OF 12 USPATFULL
ACCESSION NUMBER: 2002:236240 USPATFULL
TITLE: Trem-1 splice variant for use in modifying immune responses
INVENTOR(S): Gingras, Marie-Claude, Houston, TX, UNITED STATES
Margolin, Judith F., Houston, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002128444	A1	20020912
APPLICATION INFO.:	US 2001-21509	A1	20011207 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-254404P	20001208 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FULBRIGHT & JAWORSKI, LLP, 1301 MCKINNEY, SUITE 5100, HOUSTON, TX, 77010-3095
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 2505
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a soluble receptor variant of TREM-1. More particularly, present invention relates to methods of modulating an immune response by administering variants of TREM-1.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 12 USPATFULL
ACCESSION NUMBER: 2002:99407 USPATFULL
TITLE: Nucleic acids, proteins and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002052308	A1	20020502
APPLICATION INFO.:	US 2001-925301	A1	20010810 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2000-US5882, filed on 8 Mar 2000, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-124270P	19990312 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 30577
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to newly identified tissue specific cancer associated polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cancer antigens," and to the complete gene sequences associated therewith and to the expression products thereof, as well as the use of such tissue specific cancer antigens for detection, prevention and treatment of tissue specific disorders, particularly the presense of cancer. This invention relates to the cancer antigens as well as vectors, host cells, antibodies directed to cancer antigens and recombinant and synthetic methods for producing the same. Also provided are diagnostic methods for diagnosing and treating, preventing and/or prognosing tissue specific disorders, including cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying

agonists and antagonists of cancer antigens of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and/or function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 12 USPATFULL

ACCESSION NUMBER:	2002:84902 USPATFULL
TITLE:	Nucleic acids, proteins and antibodies
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Ruben, Steven M., Olney, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002044941	A1	20020418
APPLICATION INFO.:	US 2001-925302	A1	20010810 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2000-US5918, filed on 8 Mar 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-124270P	19990312 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS:	23
EXEMPLARY CLAIM:	1
LINE COUNT:	21121

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel lung cancer related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "lung cancer antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such lung cancer polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the lung, including, but not limited to, the presence of lung cancer and lung cancer metastases. More specifically, isolated lung cancer nucleic acid molecules are provided encoding novel lung cancer polypeptides. Novel lung cancer polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human lung cancer polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the lung, including lung cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 12 USPATFULL

ACCESSION NUMBER:	2001:229235 USPATFULL
TITLE:	METHOD FOR USING SOLUBLE CURCUMIN TO INHIBIT PHOSPHORYLASE KINASE IN INFLAMMATORY DISEASES
INVENTOR(S):	HENG, MADALENE C.Y., NORTHRIDGE, CA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001051184	A1	20011213
APPLICATION INFO.:	US 1999-315856	A1	19990520 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ATTN: DAVID A. FARAH. M.D., SHELDON & MAK, 225 SOUTH LAKE AVENUE, SUITE 900, PASADENA, CA, 91101
NUMBER OF CLAIMS: 115
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 4191
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The compound curcumin, derived from turmeric, inhibits phosphorylase kinase and, by doing so, exhibits a number of physiological effects related to the control of inflammation and cellular proliferation. However, curcumin is effective only when in solution. Curcumin is almost completely insoluble in water or in oils, but is soluble in alcohols. Accordingly, a method for treating inflammation in a mammal comprising administering curcumin in a solution containing at least one alcohol to a mammal to detectably inhibit the activity of phosphorylase kinase in the blood of the mammal or in a tissue of the mammal. The alcohol is preferably ethanol, 1-propanol, or 2-propanol; most preferably, it is ethanol. Instead of curcumin, a curcumin derivative or curcuminoid can be administered. The method can further comprise the administration of at least one additional compound that can be (1) vitamin D.sub.3 and vitamin D.sub.3 analogues; (2) vitamin A, vitamin A derivatives, and vitamin A analogues (3) a calmodulin inhibitor; (4) an anti-inflammatory drug; (5) a calcium channel blocker; (6) a H1 or H2 histamine blocker; (7) an antioxidant; (8) a polyphenolic compound; (9) a monoterpene; (10) genistein; (11) a soybean derived lectin; and (12) dehydrozingerone. Another aspect of the present invention is a pharmaceutical composition comprising curcumin, a curcuminoid, or a curcumin derivative in a solution containing at least one alcohol, at least one additional compound as described above, and a pharmaceutically acceptable carrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 12 MEDLINE DUPLICATE 1
ACCESSION NUMBER: 2000098103 MEDLINE
DOCUMENT NUMBER: 20098103 PubMed ID: 10634615
TITLE: Effects of 1alpha,25-dihydroxyvitamin D3 on **Langerhans** cell **migration** and corneal neovascularization in mice.
AUTHOR: Suzuki T; Sano Y; Kinoshita S
CORPORATE SOURCE: Department of Ophthalmology, Kyoto Prefectural University of Medicine, Japan.. tsuzuki@ophth.kpu-m.ac.jp
SOURCE: INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE, (2000 Jan) 41 (1) 154-8.
Journal code: 7703701. ISSN: 0146-0404.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200001
ENTRY DATE: Entered STN: 20000131
Last Updated on STN: 20000131
Entered Medline: 20000114

AB PURPOSE: To examine the effects of 1alpha,25-dihydroxyvitamin D3 (1alpha,25[OH]2D3), a hormone that has immunosuppressive properties, on **Langerhans** cell (LC) **migration** and corneal

neovascularization in mouse corneas. METHODS: Two 10-0 nylon interrupted sutures were placed in the center of 50 BALB/c mouse corneas to induce LC **migration** and corneal neovascularization. The mice were then randomly assigned to one of five groups. Three groups (n = 11, n = 11, n = 6) received topical 1alpha,25(OH)2D3 (at concentrations of 10(-7) M, 10(-)8 M, 10(-9) M), one group (n = 11) received vehicle only, and one group (n = 11) received no eye drops. Instillation (three times a day) began on the first day after suturing. Corneal neovascularization was assessed by slit lamp microscopy and scored according to the length of newly formed corneal vessels. Fourteen days after suturing, the number of LCs that had migrated into the central corneal epithelium was counted by an immunofluorescence assay using an anti-Ia antibody. RESULTS: The number of LCs in the central cornea was 21.9 +/- 2.8 cells/mm2 in the nontreated group and 17.8 +/- 3.9 cells/mm2 in the vehicle-only group. Significantly fewer LCs were detected in all groups that had received 1alpha,25(OH)2D3 compared with the vehicle only and nontreated groups (10(-7) M: 7.4 +/- 1.2 cells/mm2, 10(-8) M: 7.2 +/- 2.0 cells/mm2, 10(-9) M: 6.2 +/- 0.7 cells/mm2). Moderate inhibition of corneal vascularization was observed in the 10(-7) M 1alpha,25(OH)2D3 group, but not the other groups. CONCLUSIONS: Topical administration of 1alpha,25(OH)2D3 can be effective in suppressing ocular surface inflammation by inhibiting LC **migration** into mouse corneas.

L6 ANSWER 8 OF 12 MEDLINE
ACCESSION NUMBER: 2000084977 MEDLINE
DOCUMENT NUMBER: 20084977 PubMed ID: 10617914
TITLE: Regulatory effects of 1alpha,25-dihydroxyvitamin D(3) on cytokine production by human corneal epithelial cells.
AUTHOR: Suzuki T; Sano Y; Sotozono C; Kinoshita S
CORPORATE SOURCE: Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan.. tsuzuki@ophth.kpu-m.ac.jp
SOURCE: CURRENT EYE RESEARCH, (2000 Feb) 20 (2) 127-30. Journal code: 8104312. ISSN: 0271-3683.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200004
ENTRY DATE: Entered STN: 20000413
Last Updated on STN: 20000413
Entered Medline: 20000405

AB PURPOSE: The topical administration of 1alpha,25-dihydroxy-vitamin D(3) [1alpha,25(OH)(2)D(3)] inhibits **Langerhans** cell (LC) **migration** and corneal neovascularization in mice. Since the cytokines that induce LC **migration** [e.g. interleukin-1 (IL-1)] and corneal neovascularization [e.g. interleukin-8 (IL-8)] are produced by human corneal epithelial cells, we investigated the inhibitory effects of 1alpha,25(OH)(2)D(3) on cytokine production by these cells in vitro. METHODS: In this experiment, human corneal epithelial cells, cultured in DMEM-FBS until confluence, were then switched to serum-free DMEM containing insulin, transferrin, and sodium selenite (DMEM-ITS) for 48 hours. Next, they were cultured with DMEM-ITS containing 1alpha,25(OH)(2)D(3) at concentrations of 10(-7) M, 10(-11) M, or 10(-15) M, and vehicle only (0.1% ethanol). After 6 or 12 hours in this culture, the supernatants were collected and concentrations of IL-1alpha, IL-1b, and IL-8 were quantified by ELISA. RESULTS: Significantly lower levels of IL-1alpha and IL-1b were detected in supernatants from cells cultured with 1alpha, 25(OH)(2)D(3) (10(-7) M, 10(-11) M, and 10(-15) M), compared to cells cultured with vehicle only. This was true at 6 and 12 hours after the addition of 1alpha,25(OH)(2)D(3) ($p < 0.05$). IL-8 production inhibition by 1alpha,25(OH)(2)D(3), on the other hand, was

detected at 6 hours ($p < 0.0005$) but not at 12 hours ($p > 0.1$). CONCLUSIONS: 1alpha,25(OH)(2)D(3) inhibits cytokine (IL-1alpha, IL-1b, and IL-8) production by human corneal epithelial cells in vitro. We suspect that 1alpha,25(OH)(2)D(3) can inhibit LC **migration** and corneal neovascularization, as is seen in ocular surface inflammation.

L6 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:565918 HCAPLUS
DOCUMENT NUMBER: 131:165310
TITLE: Active vitamin D derivatives as **Langerhans** cell **migration** inhibitors for treatment of eye inflammation
INVENTOR(S): Kinoshita, Shigeru
PATENT ASSIGNEE(S): Chugai Seiyaku Kabushiki Kaisha, Japan
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9943330	A1	19990902	WO 1999-JP833	19990224
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9926393	A1	19990915	AU 1999-26393	19990224
EP 1059085	A1	20001213	EP 1999-906462	19990224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: JP 1998-44757 A 19980226
WO 1999-JP833 W 19990224

AB **Langerhans** cell **migration** inhibitors contg. activated vitamin D as the active ingredient. These inhibitors are useful in preventing inflammations caused by immune reactions in the skin or cornea and treating these inflammations after onset while showing little side effect. Eye drops contg. active vitamin D3 derivs. were prepd.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 12 USPATFULL
ACCESSION NUMBER: 1999:27178 USPATFULL
TITLE: Ophthalmic composition containing active Vitamin D
INVENTOR(S): Itoh, Seiji, Mobara, Japan
Ishii, Yasuo, Kawaguchi, Japan
Mukai, Katsuhiko, Kashiwa, Japan
Kita, Kiyoshi, Tokyo, Japan
PATENT ASSIGNEE(S): New Vision Co., Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5876709		19990302	
APPLICATION INFO.:	US 1997-863425		19970527	(8)

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: Azpuru, Carlos A.
LEGAL REPRESENTATIVE: Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 1373
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An ophthalmic composition for preventing corneal haze and corneal refraction anomaly observed after anterior ocular tissues are damaged or during corneal diseases comprises, as an effective component, vitamin D such as ergocalciferols and cholecalciferols or active vitamin D.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 12 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 1999:237641 BIOSIS
DOCUMENT NUMBER: PREV199900237641
TITLE: Regulatory effects of 1alpha,25-dihydroxyvitamin D3 on cytokine production by human corneal epithelial cells.
AUTHOR(S): Suzuki, T. (1); Sano, Y. (1); Kinoshita, S. (1)
CORPORATE SOURCE: (1) Kyoto Prefectural Univ of Med., Kyoto Japan
SOURCE: IOVS, (March 15, 1999) Vol. 40, No. 4, pp. S249. Meeting Info.: Annual Meeting of the Association for Research in Vision and Ophthalmology Fort Lauderdale, Florida, USA May 9-14, 1999 Association for Research in Vision and Opthalmology .
DOCUMENT TYPE: Conference
LANGUAGE: English

L6 ANSWER 12 OF 12 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 1998:242566 BIOSIS
DOCUMENT NUMBER: PREV199800242566
TITLE: Effect of 1alpha,25-dihydroxyvitamin D3 on **Langerhans** cell **migration** in mouse cornea.
AUTHOR(S): Suzuki, T.; Sano, Y.; Kinoshita, S.
CORPORATE SOURCE: Dep. Ophthalmol., Kyoto Prefect. Univ. Med., Kyoto Japan
SOURCE: IOVS, (March 15, 1998) Vol. 39, No. 4, pp. S774. Meeting Info.: Annual Meeting of the Association for Research in Vision and Ophthalmology Fort Lauderdale, Florida, USA May 10-15, 1998 Association for Research in Vision and Ophthalmology .
DOCUMENT TYPE: Conference
LANGUAGE: English

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	29.47	42.35

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.65	-0.65

STN INTERNATIONAL LOGOFF AT 11:03:45 ON 01 APR 2003